Welcome to our dedicated page for Healthcare Triangle news (Ticker: HCTI), a resource for investors and traders seeking the latest updates and insights on Healthcare Triangle stock.
Healthcare Triangle, Inc. reports developments in healthcare information technology, digital health platforms, cloud enablement, managed services, and data analytics for healthcare and life sciences organizations. Company news includes product and customer updates involving hospital information management, interoperability, telehealth, AI-powered clinical and operational automation, and customer-engagement tools.
Recurring HCTI updates also cover subsidiary activity at QuantumNexis, international expansion across Africa, the Middle East, and related healthcare markets, partnership and joint-venture activity, and capital-structure actions such as share repurchase authorization and reverse stock split disclosures.
Healthcare Triangle (Nasdaq: HCTI) will effect a 1-for-60 reverse stock split effective 12:01 a.m. ET on February 10, 2026, with post-split trading on Nasdaq at market open February 10, 2026, pending DTC and Nasdaq confirmations.
The split was approved by stockholders on February 2, 2026, assigns new CUSIP 42227W405, reduces outstanding shares from ~45,417,091 to ~756,952, and is intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price. Stockholders of record as of January 8, 2026 will receive post-split information from transfer agent VStock Transfer.
Healthcare Triangle (Nasdaq: HCTI) subsidiary QuantumNexis announced a joint venture with Golden Code Holdings to accelerate AI and digital health transformation in Saudi Arabia, targeting the $70 billion Saudi healthcare market by 2030. The JV will deploy interoperable, open‑standards platforms (Ezovion, Ziloy.ai, Readabl.ai, openEHR) and partner with Microsoft and Better.care to support Saudi Vision 2030, build local workforce capability, and establish a Middle East hub for innovation, research, and co‑development across hospitals, clinics, and national health programs.
Healthcare Triangle (Nasdaq: HCTI) entered a Development Program Agreement with Better to expand digital health platform services across Europe, Southeast Asia, the Middle East, and Africa. The collaboration gives HCTI and subsidiary QuantumNexis access to training, certification, and partner status to deploy Better's openEHR-based solutions.
The partnership targets market entry in India, Malaysia, Indonesia, the Philippines, Saudi Arabia, and multiple African markets and positions HCTI as a preferred service provider for Better's platform.
Healthcare Triangle (Nasdaq: HCTI) will participate in the Deal Flow Discovery Conference in Atlantic City on January 28-29, 2026 and will present at 3:00 PM on January 28, 2026. The company will showcase its healthcare cloud services, AI data platforms, digital transformation solutions, behavioural health tools, cybersecurity offerings, and international acquisition road map.
HCTI management will hold one-on-one investor meetings to discuss its technology roadmap, market opportunities, and long-term value creation strategy.
Healthcare Triangle (Nasdaq: HCTI) signed a definitive agreement to acquire Spain-based AI CX assets run by Teyame AI, aiming to expand its SaaS footprint in Europe and Latin America.
The deal contemplates up to $50 million in total consideration (cash, common stock, non-voting convertible preferred stock, and contingent earnout equity), targets a closing on Jan 29, 2026 subject to shareholder approval, and is effective Jan 1, 2026 for accounting. The assets reported ~$32M revenue and ~$3.6M EBITDA for FY2025; the company forecasts incremental $38M NTM revenue and $5M NTM EBITDA.
Healthcare Triangle (Nasdaq: HCTI) signed an Advance Agreement to acquire Spain-based AI customer engagement Assets run by Teyame AI, targeting a closing in Q1 2026 subject to a definitive purchase agreement, due diligence, shareholder approval, and customary conditions. The contemplated deal values consideration at up to approximately $50 million in cash, common stock, non-voting convertible preferred stock and contingent earnouts. The company expects the Assets to generate ~$34 million incremental revenue and $4.2 million incremental EBITDA for fiscal year 2025, and to expand HCTI's AI-driven patient engagement and global SaaS strategy.
Healthcare Triangle (Nasdaq: HCTI) signed a non-binding Letter of Intent to acquire assets of Spain-based Teyame.AI, an AI-driven omnichannel customer experience platform. Based on information received, Teyame is expected to generate approximately $34 million in revenue and $4.2 million in EBITDA for fiscal 2025. The combination aims to create a global, AI-powered patient engagement platform by integrating Teyame's Agentic Gen AI, multilingual automation, and analytics with HCTI's clinical systems and QuantumNexis products.
Anticipated impacts include expanded international reach (Europe, LATAM, MENA, APAC), cross-selling into HCTI's hospital and clinic network, enhanced digital mental health workflows, and tighter front-end to back-end clinical integration. The LOI remains non-binding and subject to completion.
Healthcare Triangle (Nasdaq: HCTI) entered into warrant exercise agreements with certain accredited and institutional investors to immediately exercise an aggregate of 239,051 existing warrants for gross cash proceeds of approximately $478,000. The company agreed to reduce the existing warrant exercise price from $20.92 to $2.00 per share.
In a private placement, the exercising holders will receive new unregistered warrants to purchase up to 239,051 shares at an exercise price of $3.00 per share; the New Warrants are immediately exercisable and expire five years from issuance. The transactions and closing are expected on or about October 8, 2025. WallachBeth Capital acted as financial advisor.
Healthcare Triangle (Nasdaq: HCTI) announced on Oct 3, 2025 that holders agreed to immediately exercise outstanding warrants to buy 377,702 common shares for aggregate gross proceeds of approximately $755,000. In return, those holders will receive new unregistered warrants to purchase up to 377,702 shares at an exercise price of $3.00 per share.
The company reduced the exercise price of the Existing Warrants from $20.92 to $2.00. The New Warrants are immediately exercisable, expire five years from issuance, and the transactions are expected to close on or about Oct 6, 2025. WallachBeth Capital is acting as financial advisor. Gross proceeds exclude any future New Warrant exercises and will be reduced by advisor fees and transaction expenses.
Healthcare Triangle (NASDAQ:HCTI) has secured approximately $1.63 million in gross proceeds through warrant exercise agreements with three existing accredited investors. The agreement involves the immediate exercise of existing warrants to purchase 812,775 shares of common stock, with the exercise price reduced from $20.92 to $2.00 per share.
In exchange, investors will receive new unregistered warrants to purchase an additional 812,775 shares at $3.00 per share, exercisable upon stockholder approval and expiring five years thereafter. WallachBeth Capital is serving as the sole placement agent for this warrant inducement transaction, expected to close on October 2, 2025.